Thalys corrects the equity structure of the capital increase and investment announcement of its subsidiary

Thalys Medical Technology Group Co., Ltd. issued a correction announcement. The company disclosed on September 18th the "Announcement on the External Investment of Capital Increase in the Joint Venture Subsidiary and Joint Investment with the Actual Controller, as well as Related Transactions," which contained some errors and is now being corrected. The main adjustment is in the shareholder names and corresponding shareholding ratios in the equity structure of the target company after the acquisition is completed. The shareholding ratio of "Thalys Medical" changed from 49.00% to 41.00%, while "Wei Xin Biological" changed from 41.00% to 49.00%. At the same time, the relevant information in the "2025 Fifth Extraordinary Shareholders' Meeting Materials" is also being corrected. Other contents of the original announcement remain unchanged. The company apologizes for the inconvenience caused by this correction and will strengthen the review of information disclosure